Wednesday, August 20, 2025
Given the undeniably novel aspect of this new paradigm, however, conducting CAR-T clinical trials presents a unique set of obstacles for sponsors, sites and regulators to carefully navigate. Moreover, the complexity of manufacturing, delivering and managing genetically modified cells has made CAR-T trials both operationally intensive and logistically demanding.